Eighty-two-year-old patient with a pacemaker using warfarin due to arrhythmia and having an intraocular lens in the right eye, developed spontaneous hemorrhagic choroidal detachment one day after the use of combined preparation of 0.5% timolol maleate and 0.004% travoprost, due to primary open-angle glaucoma. Hemorrhagic detachment was detected by anterior and posterior segment examination, as ...

We describe a 66-year-old man who developed bilateral choroidal detachment that was induced by unilateral topical administration of a fixed combination of 1% brinzolamide and 0.5% timolol maleate the day after an uneventful phacoemulsification surgery and intraocular lens implantation involving his right eye. We believe that the reaction was an idiosyncratic reaction, most likely against brinzo...

The fixed combination eye drop Duotrav is a combination of travoprost 0.004% and timolol maleate 0.5%. Both travoprost and timolol have been used separately for the treatment of glaucoma by lowering intraocular pressure. Multiple studies have demonstrated the efficacy and safety of the fixed combination travoprost/timolol for the treatment of open-angle glaucoma and ocular hypertension. The onc...

the purpose of this study was preparation and evaluation of sustained release matrix type ocular mini-tablets of timolol maleate, as a potential formulation for the treatment of glaucoma. following the initial studies on timolol maleate powder, it was formulated into ocular mini-tablets. the polymers investigated in this study included cellulose derivatives (hec, cmc, ec) and carbopol971p. mann...

Timolol Maleate (also called Timolol) is a nonselective beta-adrenergic blocker and a class II antiarrhythmic drug, which is used to treat intraocular hypertension. It has been reported to cause systemic side effects especially in elderly patients with other comorbidities. These side effects are due to systemic absorption of the drug and it is known that Timolol is measurable in the serum follo...

OBJECTIVE To evaluate 24-hour intraocular pressure (IOP) control with an evening-dosed latanoprost-timolol maleate fixed combination vs timolol alone in patients with primary open-angle glaucoma. METHODS After a medicine-free period, qualified patients were randomized to either placebo dosed in the morning with a latanoprost-timolol fixed combination dosed in the evening or timolol alone dose...

Lowering IOP is the most readily modifiable risk factor to delay the development and progression of glaucoma (POAG). The fixed combination of brimonidine tartrate 0.2% and timolol maleate 0.5% (FCBT) combines a highly selective alpha2-adrenergic agonist (brimonidine) with a non-selective beta-blocker (timolol). FCBT reduces aqueous production and enhances uveoscleral outflow. Concomitant brimon...

BACKGROUND The serendipitous discovery of propranolol as a medical therapy for infantile hemangioma in 2008 resulted in a significant change in the treatment paradigm for patients with hemangioma. The use of systemic propranolol is now widely used, either alone or in conjunction with other medications or surgical treatments. Although generally well tolerated, propranolol is typically initiated ...

A simple method for quantifying visual field survival was devised to assess the progress of chronic simple glaucoma in 36 patients treated with timolol maleate over a 3-year period. Routine tonometric monitoring of the intraocular pressure (IOP) was carried out in conjunction with these Goldmann field studies. Statistical analysis revealed that field survival measurement provided a more consist...